GT Biopharma Inc. Common Stock
GTBPGT Biopharma Inc. (GTBP) is a biotechnology company focused on developing and commercializing targeted immunotherapies for cancer and other diseases. The company employs its proprietary technologies, including its Tri-specific Killer Engager (TriKE) platform, to design novel agents that harness the immune system to specifically attack cancer cells. GT Biopharma aims to advance innovative treatments through clinical development and strategic collaborations.
Company News
Multiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.
GT Biopharma reported progress on its Phase 1 clinical trial for GTB-3650, a TriKE® therapy targeting CD33-expressing hematologic malignancies, with successful advancement to Cohort 4 and no observed safety issues. The company plans to provide a trial update in Q1 2026 and anticipates submitting an IND for GTB-5550 in late December 2025.
GT Biopharma, Inc. (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Announced Positive Interim Data Results Demonstrating Substantial Reduction in AML/MDS Cancer Cells… The post GT Biopharma Provides Second Quarter 2021 Business Update appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
